P
Proov
Proov offers OTC at-home testing, including the only FDA cleared at-home test to confirm successful ovulation via PdG
About Proov
Proov is a healthcare company specializing in medical-quality diagnostic testing aimed at enhancing fertility and overall hormone health for women. Founded by Dr. Amy Beckley and Ellen Schell, the company offers a range of products including fertility tests, supplements, and comprehensive support services. Proov primarily serves women who are trying to conceive, those experiencing hormonal imbalances, and healthcare providers in the fertility sector. Operating in the women's health market, Proov's business model revolves around direct-to-consumer sales through their website, leveraging e-commerce to reach a broad audience. Revenue is generated through the sale of diagnostic tests, supplements, and subscription-based support services. The company differentiates itself by offering scientifically-backed, easy-to-use home testing kits that provide actionable insights into hormone levels, particularly focusing on the progesterone metabolite PdG, which is crucial for successful ovulation and pregnancy outcomes. Proov's mission is to empower women by providing them with the tools and knowledge to take control of their reproductive health.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2016
- Headquarters
- Erie, United States
- Employees
- 16
- Open positions
- None listed
- Dealroom signal
- 31.1/100
- Industry
- Health
- Sub-industry
- Health Platform
- Sector
- Health Tech & Medtech, Fertility, Femtech, Sustainable Development Goals, Tech for Patients, Reproductive Health, Hard Tech
- Business model
- Marketplace & ecommerce
- Client focus
- b2c
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ANGEL✓Equity / VC | Apr 2024 | — | — | Undisclosed | ↗ |
| SERIES A✓Equity / VC | Dec 2021 | $9.7M | $39M | GingerBread Capital · Lightship Capital · Hambrecht Ducera Growth Ventures · Portfolia Funds | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Proov is 170K monthly website visits, up 54.5% over the last three months. Proov's team declined 23.8% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
US National Science Foundation
Series A5 investors entered at this stage
- HVHambrecht Ducera Growth Ventures
GingerBread Capital
Lightship Capital
Portfolia Funds
SteelSky Ventures
Other known investors4 additional known investors
Brian Brackeen
Kaya Ventures
Worldera- WHWR Hambrecht
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Proov on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Proov’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.